Hervolution Therapeutics

Founded in 2011 and based in Frederiksberg, Denmark, Hervolution Therapeutics formerly known as, InProTher Aps operates as a biotechnology company that engages in developing immunotherapies for patients with cancer. As of 2023, Jordi Naval serves as the CEO of the company. In May 2023, InProTher Aps raised seed funding from the European Innovation Council. The round was part of a larger EUR 6 million seed and venture debt round.

In December 2024, Hervolution Therapeutics raised USD 11. 7 million in series A funding from new investor Serum Institute of India Pvt. Ltd. , with participation from returning investor European Innovation Council.

Other unspecified investors also participated in the round. The company is developing immunotherapies that overcome the limits of cancer vaccines by targeting HERV tumour antigens with a method that stimulates both the humoral and cellular immune systems. The firm's primary product, IPT001, mutates the ISD domain within the HERV immunogen. InProTher distributes its modified immunogen as cancer vaccines using adenoviral and RNA vectors.

InProTher's technique of action focuses on the enhanced immune system's ability to resist viruses via antibodies, CD8+ T cells, and CD4+ T cells. The organization plans to use the May 2023 funding for the advancement of its research and development.